SCHEMBL4941278

SCHEMBL4941278

COc1ccc(C(=O)NNC(=S)Nc2ccc([N+](=O)[O-])cc2)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.58
RAB9A P51151 3/20 0.58
NPC1 O15118 3/20 0.58
SMN1; SMN2 Q16637 4/20 0.56
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 1/20 0.53
GAA P10253 5/20 0.53
MAPT P10636 5/20 0.52
MEN1 O00255 3/20 0.52
HPGD P15428 2/20 0.52
HTT P42858 2/20 0.52
AKR1C3 P42330 1/20 0.52
AKR1C2 P52895 1/20 0.52
HSP90AA1 P07900 1/20 0.52
PKM P14618 1/20 0.52
PAX8 Q06710 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
RXFP1 Q9HBX9 1/20 0.50
ALOX5 P09917 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4939367 0.87 KMT2A (0.69) KMT2ARAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL30354805 0.80 KMT2A (0.73) KMT2ARAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL28527153 0.79 MAPT (0.63) KMT2ARAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL13372584 0.77 KMT2A (0.54) KMT2ARAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL16587382 0.75 MAPT (0.75) KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL16149341 0.74 NPC1 (0.74) KMT2ARAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL28397435 0.74 KMT2A (0.67) KMT2ARAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL30362728 0.74 KMT2A (0.67) KMT2ARAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL28382759 0.74 ALOX5 (0.59) KMT2ARAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL5390822 0.73 KDM4E (0.60) KMT2ARAB9ANPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8618285-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2013-12-31 US disclosed
EP-1853570-B1 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-10-24 EP disclosed
CN-101119978-B HSP 90-inhibiting triazole derivatives MERCK PATENT GMBH 2012-05-23 CN disclosed
US-20080182857-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-07-31 US disclosed
CN-101119978-A HSP90-inhibiting triazole derivatives MERCK PATENT GMBH (DE) 2008-02-06 CN disclosed
EP-1853570-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES Merck Patent GmbH (DE) 2007-11-14 EP disclosed
WO-2006087077-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182857-A1 Triazole Derivatives HSP90AB1, HSP90AA1, HSP90B1 KMT2A 4070/4885RAB9A 1943/4885NPC1 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.